Werner Baumann - Bayer AG Executive
BAYZF Stock | USD 25.96 0.05 0.19% |
Executive
Mr. Werner Baumann has served as Chairman of the Management Board and Chief Executive Officer of Bayer Aktiengesellschaft since May 1, 2016. Previously he served as Member of the Management Board, Strategy and Portfolio Management, EuropeMiddle EastAfrica Region at Bayer AG from January 1, 2016 till April 30, 2016. After studying economics at RWTH Aachen Universitaet and the University of Cologne, he joined Bayer in 1988. His first duties were in the Corporationrationrate Finance Department in Leverkusen. In 1991 he transferred to Bayer Hispania Comercial in Barcelona, Spain, to take up a position as controller, becoming assistant to the managing director in 1995. A year later, Baumann moved to Bayer Corporation in Tarrytown, New York, latterly heading up the global Business Planning Administration organization of the Diagnostics Business Group. In July 2002, Baumann returned to Germany to become a member of the Executive Committee and Head of Central Administration Organization at Bayer HealthCare. In October 2003 he was appointed a member of the Board of Management of the newly formed subgroup Bayer HealthCare AG, also serving as the company Labor Director. As a member of the Board of Management and Labor Director of Bayer Schering Pharma AG, Berlin, Germany, from 2006 through September 2009, he actively participated in this company integration into the subgroup. Prior to October 1, 2014, he served as Bayer AGs Chief Financial Officer . since 2016.
Age | 61 |
Tenure | 9 years |
Phone | 49 214 30 1 |
Web | https://www.bayer.com |
Bayer AG Management Efficiency
The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer AG's management efficiency ratios could be used to measure how well Bayer AG manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Elena Lokis | Getty Realty | N/A | |
Lucas Chang | United Microelectronics | 70 | |
Edward Ferguson | IAC Inc | N/A | |
Wenchi Ting | United Microelectronics | N/A | |
M Hsu | United Microelectronics | N/A | |
Ming Hsu | United Microelectronics | N/A | |
James Flynn | Aviat Networks | N/A | |
Shane Dorcheus | Albertsons Companies | N/A | |
Steven Liu | United Microelectronics | N/A | |
Thomas Moriarty | Albertsons Companies | 61 | |
YS Shen | United Microelectronics | N/A | |
Francia Hsu | United Microelectronics | N/A | |
John Weaver | IPG Photonics | N/A | |
Joshua Koplik | IAC Inc | N/A | |
Gary Croke | Aviat Networks | 53 | |
Robert Larson | Albertsons Companies | 54 | |
Zhenlun Zhang | United Microelectronics | N/A | |
Muliang Liao | United Microelectronics | N/A | |
Jason Anderson | Titan Machinery | N/A | |
Lauren Geer | IAC Inc | N/A | |
Steve JD | Titan Machinery | N/A |
Management Performance
Return On Equity | 0.13 | |||
Return On Asset | 0.0576 |
Bayer AG Leadership Team
Elected by the shareholders, the Bayer AG's board of directors comprises two types of representatives: Bayer AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer AG's management team and ensure that shareholders' interests are well served. Bayer AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sarena Lin, Labor Officer | ||
Oliver Maier, Head Relations | ||
Gabriel Harnier, Patents Law | ||
Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division | ||
Rodrigo Santos, Member Division | ||
Michael Preuss, Gov Communications | ||
Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division | ||
Wolfgang Nickl, CFO, Member of the Management Board | ||
BerndPeter Bier, Head Taxes | ||
Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board |
Bayer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.13 | |||
Return On Asset | 0.0576 | |||
Profit Margin | 0.09 % | |||
Operating Margin | 0.23 % | |||
Current Valuation | 87.41 B | |||
Shares Outstanding | 982.42 M | |||
Shares Owned By Institutions | 47.11 % | |||
Price To Earning | 321.83 X | |||
Price To Book | 1.36 X | |||
Price To Sales | 1.06 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Bayer Pink Sheet
Bayer AG financial ratios help investors to determine whether Bayer Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bayer with respect to the benefits of owning Bayer AG security.